Preferences help
enabled [disable] Abstract
Number of results
2018 | 8 | 3 | 86-93
Article title

Time to treatment of prostate cancer patients

Title variants
Languages of publication
Prostate cancer is one of the most common cancers in men. The incidence of prostate cancer increases systematically. The correlation between waiting time for oncological treatment and survival prognosis in prostate cancer is not clearly determined. The aim of the study was to estimate the waiting time from suspicion until prostate cancer diagnosis and treatment in Warmia and Mazury Voivodeship. Ninety-six consecutive prostate cancer patients treated with radical radiotherapy between November 2016 and June 2017 in the Department of Radiation Oncology of the Hospital of the Ministry of Internal Affairs with Warmia and Mazury Oncology Center in Olsztyn were included in the analysis. A questionnaire prepared especially for this study, and individual interviews with patients were used in the study. The obtained data was supplemented with medical records and hospital databases. In the case of twenty-nine men, the PSA concentration was measured due to urinary disorders, and the median time from symptoms until the first PSA test in that group was 168 days. The median time from PSA concentration > 4 ng/ml to biopsy of prostate cancer and start of treatment for all patients was 62 and 156 days, respectively. Hormone therapy was administered the quickest. A positive correlation was observed between the waiting time from histopathological confirmation of prostate cancer until treatment, and the distance from one’s place of residence to the oncological center (p < 0.05).
Physical description
  • Department of Oncology, University of Warmia and Mazury in Olsztyn
  • Department of Public Health, Epidemiology and Microbiology, University of Warmia and Mazury in Olsztyn
  • Student Scientific Society of the Department of Oncology, University of Warmia and Mazury in Olsztyn
  • Student Scientific Society of the Department of Oncology, University of Warmia and Mazury in Olsztyn
  • Student Scientific Society of the Department of Oncology, University of Warmia and Mazury in Olsztyn
  • Department of Oncology, University of Warmia and Mazury in Olsztyn
  • 1. Stewart BW, Wild CP. World Cancer Report 2014. International Agency for Research on Cancer. World Health Organization 2014.
  • 2. [online:].
  • 3. Rao AR, Motiwala HG, Karim O. The discovery of prostate-specific antigen. BJU Int 2008; 101: 5-10.
  • 4. Sandhu GS, Andriole GL. Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr 2012: 146-151.
  • 5. Rove KO, Crawford ED. Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts. World J Urol 2012; 30: 137-142.
  • 6. van den Bergh RCN, Albertse PC, Bangma CH et al. Timing of curative treatment for prostate cancer: A systematic review. Eur Urol 2013; 64: 204- -215.
  • 7. Freedland SJ, Kane CJ, Amling CL et al. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol 2006; 175: 1298-1303.
  • 8. Nam RK, Jewett MA, Krahn MD et al. Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. Can J Urol 2003; 10: 1891-1898.
  • 9. Graefen M, Walz J, Chun KHF et al. Reasonable delay of surgical treatment in men with localized prostate cancer – impact on prognosis? Eur Urol 2005; 47: 756-760.
  • 10. Siemens DR, Schulze KM, Mackillop WJ et al. A population-based study of the waiting times for prostatectomy in Ontario. Can J Urol 2005; 12: 2568-2574.
  • 11. Nakayama H, Kanemoto A, Kikuchi K et al. Delayed radiotherapy for patients with localized prostate cancer: validation by propensity score matching. Anticancer Res 2013; 33: 1629-1633.
  • 12. Nguyen PL, Whittington R, Koo S et al. The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. Cancer 2005; 103: 2053-2059.
  • 13. Andrews SF, Horwitz EM, Feigenberg SJ et al. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? Cancer 2005; 104: 299-304.
  • 14. Saad F, Finelli A, Dranitsaris G et al. Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literature. Can J Urol 2006; 13(Suppl 3): 16-24.
  • 15. Fitch MI, Gray RE, McGowan T et al. Travelling for radiation cancer treatment: Patient perspectives. Psycho-Oncol 2003; 12: 664-674.
  • 16. Steineck G, Helgesen F, Adolfsson J et al. Quality of life after radical prostatectomy or watchful waiting. NEJM 2002; 347: 790-796.
  • 17. Saegrov S, Halding AG. What is it like living with the diagnosis of cancer? Eur J Cancer Care 2004; 13: 145-153.
  • 18. Chen Z, King W, Pearcey R et al. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol 2008; 87: 3-16.
  • 19. van Harten MC, Hoebers FJP, Kross KW et al. Determinants of treatment waiting times for head and neck cancer in the Netherlands and their relation to survival. Oral Oncol 2015; 51: 272-278.
  • 20. Montella M, Crispo A, Botti G et al. An assessment of delays in obtaining definitive breast cancer treatment in Southern Italy. Breast Cancer Res Treat 2001; 66: 209-215.
  • 21. Richards MA, Westcombe AM, Love SB et al. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 1999; 353: 1119-1126.
  • 22. Buchholz TA, Austin-Seymour MM, Moe RE et al. Effect of delay in radiation in combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys 1993; 26: 23-35.
  • 23. Nixon AJ, Recht A, Neuberg D et al. The relation between the surgery–radiotherapy interval and treatment outcome in patients treated with breast-conserving surgery and radiation therapy without systemic therapy. Int J Radiat Oncol Biol Phys 1994; 30: 17-21.
  • 24. Froud PJ, Mates D, Jackson JS et al. Effect of time interval between breast-conserving surgery and radiation therapy on ipsilateral breast recurrence. Int J Radiat Oncol Biol Phys 2000; 46: 363-372.
  • 25. Choan E, Dahrouge S, Samant R et al. Radical radiotherapy for cervix cancer: The effect of waiting time on outcome. Int J Radiat Oncol Biol Phys 2005; 61: 1071-1077.
  • 26. Stevens C, Bondy SJ, Loblaw DA. Wait times in prostate cancer diagnosis and radiation treatment. Can Urol Assoc J 2010; 4: 243-248.
  • 27. Johnston GM, MacGarvie VL, Elliott D et al. Radiotherapy wait times for patients with diagnosis of invasive cancer, 1992-2000. Clin Invest Med 2004; 27: 142-156.
  • 28. Bardell T, Belliveau P, Kong W et al. Waiting times for cancer surgery in Ontario: 1984-2000. Clin Oncol 2006; 18: 401-409.
  • 29. Osowiecka K, Rucińska M, Nawrocki S. Have actual waiting times been reduced by introducing the DILO reform for cancer patients in Poland? Nowotwory. J Oncol 2017; 67: 168-173.
  • 30. Tran K, Sandoval C, Rahal R et al. Wait times for prostate cancer treatment and patient perceptions of care in Canada: a mixed-methods report. Curr Oncol 2015; 22: 361-364.
  • 31. Neal RD, Allgar VL. Sociodemographic factors and delays in the diagnosis of six cancers: analysis of data from the “National Survey of NHS Patients: Cancer.” Br J Cancer 2005; 92: 1971-1975.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.